Rxo (RXO) Other Non-Current Liabilities (2021 - 2026)

Rxo (RXO) has 6 years of Other Non-Current Liabilities data on file, last reported at $63.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 28.41% year-over-year to $63.0 million; the trailing twelve-month figure through Mar 2026 stood at $63.0 million (down 28.41% YoY), and the FY2025 full-year result was $69.0 million, down 16.87% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $63.0 million, down from $69.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $88.0 million in Q1 2025 and bottomed at $36.0 million in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $42.0 million (2024), against an average of $54.7 million.
• The widest annual swing landed in 2025, when Other Non-Current Liabilities surged 114.63%; it then fell 28.41% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $40.0 million in 2022, then changed by 0.0% to $40.0 million in 2023, then soared by 107.5% to $83.0 million in 2024, then fell by 16.87% to $69.0 million in 2025, then retreated by 8.7% to $63.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $63.0 million (Q1 2026), $69.0 million (Q4 2025), and $71.0 million (Q3 2025), per Business Quant data.

Peer Comparison